Evidence map›Paper›PMID 42830869›Full record

ArticleMedComm2026

Envonalkib Versus Crizotinib in Treatment-Naive

Jie Huang, Yuanyuan Wang, Haishuang Sun, Jie Min, Nong Yang, Qitao Yu, Ying Cheng, Yanqiu Zhao, Manxiang Li, Hong Chen and 16 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04009317 (A Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04009317 phase3unknown statusnot on this map

A Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

TypeinterventionalSponsorChia Tai Tianqing Pharmaceutical Group Co., Ltd.Ran2019 to 2022Enrolled260ConditionsALK-positive NSCLCArmsTQ-B3139, Crizotinib
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Jie Huang *Department of Medical Oncology State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou China.
Yuanyuan Wang *Department of Medical Oncology State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou China.
Haishuang Sun *Department of Medical Oncology State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou China.
Jie MinDepartment of Oncology The Second Affiliated Hospital of Air Force Medical University Xi'an China.
Nong YangDepartment of Medical Oncology (Lung Cancer and Gastrointestinal Unit) Hunan Cancer Hospital The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China.
Qitao YuDepartment of Medical Oncology of Respiratory Affiliated Tumor Hospital of Guangxi Medical University Nanning China.
Ying ChengDepartment of Thoracic Medical Oncology Jilin Provincial Cancer Hospital Changchun China.
Yanqiu ZhaoDepartment of Medical Oncology The Affiliated Cancer Hospital of Zhengzhou University Zhengzhou China.
Manxiang LiDepartment of Respiratory First Affiliated Hospital of Xi'an Jiaotong University Xi'an China.
Hong ChenDepartment of Respiratory and Critical Care Medicine The First Affiliated Hospital of Chongqing Medical University Chongqing China.
Shouan RenDepartment of Respiratory The First Hospital of Shanxi Medical University Taiyuan China.
Jianying ZhouDepartment of Respiratory Disease The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China.
Wu ZhuangDepartment of Medical Oncology Fujian Cancer Hospital Fuzhou China.
Xintian QinThe First Department of Oncology The First Affiliated Hospital of Guangdong Pharmaceutical University Guangzhou China.
Lejie CaoDepartment of Respiratory and Critical Care Medicine Anhui Provincial Hospital Hefei China.
Yan YuDepartment of Respiratory Medicine Affiliated Cancer Hospital of Harbin Medical University Harbin China.
Jian ZhangDepartment of Respiratory Medicine The First Affiliated Hospital of Air Force Medical University Xi'an China.
Jianxing HeDepartment of Cardiothoracic Surgery The First Affiliated Hospital of Guangzhou Medical College, Guangzhou Research Institute of Respiratory Disease, China State Key Laboratory of Respiratory Disease Guangzhou China.
Jifeng FengDepartment of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research The Affiliated Cancer Hospital of Nanjing Medical University Nanjing China.
Hao YuDepartment of Biostatistics Nanjing Medical University Nanjing China.
Lin ZhangDepartment of Medical Oncology State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou China.
Xinyuan ZhaoDepartment of Medical Oncology State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou China.
Wenfeng FangDepartment of Medical Oncology State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou China.
Jing LiDepartment of Experimental Research State Key Laboratory of Oncology in South China Sun Yat-sen University Cancer Center Guangzhou China.
Li ZhangDepartment of Medical Oncology State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou China.
Yunpeng YangDepartment of Medical Oncology State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat-sen University Cancer Center Guangzhou China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study reports efficacy and biomarker results from a multicenter, randomized, open-label Phase III study (NCT04009317). Treatment-naive anaplastic lymphoma kinase (

Indexed as

anaplastic lymphoma kinasebiomarkerscirculating tumor DNAenvonalkibnon‐small cell lung cancer

Identifiers

PMID42830869
PMCPMC13634175

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.